

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 1/00, 5/06, 15/18, C08B 37/00	A1	(11) International Publication Number: WO 98/38197 (43) International Publication Date: 3 September 1998 (03.09.98)
(21) International Application Number: PCT/AU98/00131 (22) International Filing Date: 27 February 1998 (27.02.98) (30) Priority Data: PO 5367 28 February 1997 (28.02.97) AU (71) Applicant (for all designated States except US): ALCHEMIA PTY. LTD. [AU/AU]; Suite 4, 7 Primrose Street, Sherwood, QLD 4075 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): TOTH, Istvan [GB/GB]; 195 Church Road, Northolt, Middlesex UB5 5BE (GB). DEKANY, Gyula [HU/GB]; 157 Herlwyn Avenue, Ruislip, Middlesex HA4 6HS (GB). KELLAM, Barry [GB/GB]; 93 Poplar Grove, Maidstone, Kent ME16 0AL (GB). (74) Agent: GRIFFITH HACK; 509 St. Kilda Road, Melbourne, VIC 3004 (AU).		(81) Designated States: AU, CA, CN, HU, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: PROTECTED AMINOSUGARS (57) Abstract The invention provides amine-protecting groups for use in solution phase or solid-phase oligosaccharide synthesis, in which a 2-substituted 1,3-dioxo compound is used to protect one or more primary amine groups of an aminosugar or glycosylamine. The invention provides reagents, reagent kits, and methods for solution phase, solid-phase oligosaccharide synthesis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROTECTED AMINOSUGARS

This invention relates to methods for synthesis of oligosaccharides, especially those oligosaccharides which comprise amino sugar residues. In particular the invention relates to methods for solution phase, solid phase or combinatorial synthesis of oligosaccharides.

BACKGROUND OF THE INVENTION

Aminosugars are important constituents of various glycoconjugates (Schmidt and Kinzy, 1994). Examples include peptidoglycans, mucopolysaccharides, glycopeptides and proteins, oligosaccharides of human milk, and blood group determinants. They are often also encountered in bacterial and tumour-associated carbohydrate antigens, predominantly in the N-acetylated form or N-acylated with an aspartic acid residue (Toyokuni and Singhal, 1995). It is therefore evident that these biological glycoconjugates are of immense interest to the medicinal chemist, and therefore that there is a great need in the art to be able to synthesise these compounds in a facile and cost-effective manner.

Oligosaccharide synthesis using aminosugars requires the presence of a suitable amino protecting group. A number of protecting groups have been proposed, but so far all of the agents which are available suffer from serious disadvantages. For example, glycosylation with donors derived from 2-N-acetyl protected aminosugars proceeds via neighbouring group participation; however, formation of the relatively stable oxazoline intermediate dramatically reduces the overall speed and yield of the reaction (Zurabyan et al, 1994). Therefore, various 2-deoxy-2-aminosugar donors, displaying the neighbouring group activity described, but lacking the ability to form stable oxazolines, have been developed; the most widely used of these are the phthalimido protected monomers (Sasaki et al, 1978). The phthalimide group participates

strongly during glycoside formation and gives excellent stereocontrol of the 1,2-trans-glycoside product (Lemieux *et al*, 1982), furthermore the aminosugar donors do not form stable orthoamides (Lemieux *et al*, 1982) and cannot form oxazolines. The major disadvantage of using the phthalimide group lies in the vigorous conditions required for its removal, namely heating with methanolic hydrazine, which often results in partial product decomposition. Strongly basic conditions are also required for the removal of the *N*-sulfonyl (Griffith and Danishefsky, 1990) and *N*-haloacetyl protecting groups (Shapiro *et al*, 1967), resulting in similar problems.

The allyloxycarbonyl (Alloc) protected amino sugar donors display a similar activity to their phthalimide counterparts when employed under Lewis acid-catalysed conditions. However, the Alloc group has the advantage that it can be removed under extremely mild conditions, using tetrakis (triphenylphosphine) palladium in the presence of a mild base (Hayakawa *et al*, 1986). The major disadvantage associated with the Alloc group lies in its ability to form a stable oxazolidinone intermediate, which in the presence of unreactive acceptors tends to remain as the major product, and reduces the speed and yield of the reaction (Boullanger *et al*, 1987). 2,2,2-Trichloroethyl-protected aminosugars contain a strongly participating group that, unlike phthalimide, does not deactivate adjacent hydroxyl groups which may subsequently be required as glycosyl acceptors. They can be removed under relatively mild and selective conditions, using zinc and acetic acid, and do not form oxazoline intermediates during glycosylation. However, this protecting group has the disadvantage that benzyl groups cannot be introduced without premature loss of the protecting group as well (Imoto *et al*, 1987).

Tetrachlorophthaloyl-protected aminosugar donors have been demonstrated to afford high yields of 1,2-trans-glycosides (Castro-Palomino and Schmidt, 1995), even in the

presence of poorly reactive acceptors. Once more, however, the NaBH₄-mediated deprotection is the limiting factor for this particular protecting group.

The azide group has received much attention in
5 aminosugar chemistry, since it serves as a masked, non-participating amino functionality, thereby allowing the synthesis of 1,2-*cis*-linked 2-amino-2-deoxy glycosides (Palsen, 1982). However the preparation of 2-azido-2-deoxy
10 sugars is protracted, costly, and often dangerous, using either azidonitration (Lemieux and Ratcliffe, 1979), diazo-transfer reactions (Buskas et al, 1994), azidochlorination (Bovin et al, 1986), nitrosation of *N*-benzyl derivatives (Dasgupta and Garegg, 1989) or reactions of 1,6-anhydrosugars (Tailler et al, 1991 and Paulsen and Stenzel,
15 1978).

Other non-participating protecting groups that have been reported are 2,4-dinitrophenyl (Kaifu and Osawa, 1977) and *p*-methoxybenzylimino (Mootoo and Fraser-Reid, 1989), both of which are complicated to introduce and
20 require harsh deprotection conditions which result in loss of product.

A hydrazine-labile primary amino-protecting group, *N*-1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde), has been reported for protection of lysine side
25 chains during SPPS (Bycroft et al, 1993). This group was modified for use as a carboxy-protecting group in SPPS when the 2-(3-methylbutyryl)dimedone analogue of 2-acetyldimedone was condensed with 4-aminobenzylalcohol to afford 4-[*N*-[1-(4,4-dimethyl-2,6-dioxocyclo-hexylidene)-3-
30 methylbutyl]-amino]benzyl ester (ODmab) (Chan et al, 1995). These two protecting groups were reported to be stable to the Fmoc deprotecting conditions widely used in solid phase peptide synthesis (SPPS), ie 20% piperidine in dimethylformamide (DMF).


35 Dde has been widely used in the field of SPPS as an orthogonal amino protecting group to the well established Fmoc/*t*-Boc methodology (Fields and Noble,

1990). Until now its use has remained within this area, and therefore its use as a protecting group in the field of carbohydrate chemistry is novel. In particular, the use of Dde or ODMab in oligosaccharide synthesis has not been suggested.


We have now surprisingly found that Dde can be used as a non-participating amino sugar protecting group, which can be introduced and removed in a facile and cost-effective manner. We have shown that the vinylogous amide protection afforded by the Dde type group is achieved by simply refluxing the unprotected amino sugar with the precursor, eg. 2-acetyldimedone in the case of Dde, in anhydrous ethanol. Using a Dde-protected aminosugar, we have performed a variety of chemical modifications upon the protected molecule in order to demonstrate the stability of this vinylogous amide type protection towards commonly encountered reactions involved in carbohydrate modification.

SUMMARY OF THE INVENTION

In one aspect, the invention provides a compound useful as a reagent for solution and/or solid phase synthesis of sugar-containing compounds, comprising a sugar carrying one or more primary amine groups protected with a 2-substituted-1,3-dioxo compound of General Formula I or General Formula II:



I



II

in which

R¹ and R² may be the same or different, and is each hydrogen or C₁₋₄ alkyl,

R' is an amino sugar, a glycosylamine, or an oligosaccharide comprising at least one aminosugar or one
5 glycosylamine unit, in which the sugar is coupled via an amino group,

and R'' is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl or substituted cycloalkyl.

Any sugar or oligosaccharide bearing an amino
10 group may be used.

In a preferred embodiment, the invention provides a reagent for solution phase synthesis of sugar-containing compounds, comprising a cyclic 2-substituted-1,3-dioxo compound of General Formula I or II as defined above, in
15 which R' is as defined above.

The compounds of the invention are suitable for use in methods of solid-phase oligosaccharide synthesis, in which sugar units are covalently linked to a resin. Any suitable linker compound may be used. For example, the
20 covalent linkage to the resin may suitably be provided by a -CONH-, -O-, -S-, -COO-, -CH=N-, -NHCONH-, -NHCSNH, or -NHNH- grouping, eg. Spacer-CONH-resin, Spacer-O-resin, Spacer-S-resin, Spacer-CO₂-resin, Spacer-CH=N-resin, Spacer-NHCONH-resin, Spacer-NHCSNH-resin, Spacer NHNH-
25 resin. Other possible covalent linking groups will be known to those skilled in the art. It is contemplated that linkers and methods described in our International Patent Application No. PCT/AU97/00544 filed on 26 August 1997, are suitable for use with the compounds of this invention. The
30 entire disclosure of PCT/AU97/00544 is incorporated herein by this cross-reference. These linker systems enable solid phase synthesis of oligosaccharides under mild conditions analogous to those used for SPPS.

The resin may be any resin which swells in water
35 and/or in an organic solvent, and which comprises one of the following substituents: halogen, hydroxy, carboxyl, SH, NH₂, formyl, SO₂NH₂, or NHNH₂, for example

methylbenzhydrylamine (MBHA) resin, amino or carboxy tentagel resins, paraaminomethylbenzyl (PAM) resin, or 4-sulphamylbenzyl AM resin. Other suitable resins will be known to those skilled in the art.

5 Thus in a second aspect the invention provides a linker-saccharide complex, comprising a linker group and a saccharide compound comprising a protecting group of general formula I or II as defined above, in which the group R' is as defined above.

10 In a third aspect the invention provides a resin-linker-saccharide support for solid-phase oligosaccharide synthesis, comprising a linker group, a resin, and a starting saccharide compound comprising a protecting group of General Formula I or General Formula II as defined
15 above, in which the group R' is as defined above.

Any suitable linker may be used. Again, it is contemplated that linkers and methods described in PCT/AU97/00544 may be used.

20 In a fourth aspect the invention provides a method of solid-phase synthesis of oligosaccharides, comprising the step of sequentially linking mono- or oligosaccharide groups, one or more of which is protected as described above, to a resin-linker-saccharide support as described above.

25 In a fifth aspect the invention provides a method of solution phase synthesis of oligosaccharides, comprising the step of sequentially linking mono- or oligosaccharide groups to a linker-saccharide complex as described above.

30 These methods are particularly useful for combinatorial synthetic applications. The solid phase or solution phase method of the invention may, for example, be used for combinatorial synthesis of aminoglycoside compounds. It will be appreciated that the sequential linkage may be effected either enzymically or by chemical
35 means.

The invention also provides a kit for solid phase synthesis, solution phase synthesis, or combinatorial

synthesis of oligosaccharides, comprising a linker-saccharide complex or a resin-linker-saccharide support according to the invention, as described above. The kit may optionally also comprise one or more further reagents such as partially or differentially activated, fully protected saccharides, protecting agents, deprotecting agents, resins and/or solvents suitable for solid phase or combinatorial synthesis. The person skilled in the art will be aware of suitable further reagents. Different types of kit can then be chosen according to the desired use.

For the purposes of this specification it will be clearly understood that the word "comprising" means "including but not limited to", and that the word "comprises" has a corresponding meaning.


DETAILED DESCRIPTION OF THE INVENTION

Abbreviations used herein are as follows:

20	Ac	acetyl
	Bu	butyl
	Dde	N-1-(4,4-Dimethyl-2,6-dioxocyclohexylidene)-ethyl
	DMF	N,N'-Dimethylformamide
	EtOH	Ethanol
25	FAB-MS	Fast atom bombardment mass spectrometry
	Me	Methyl
	MeOH	Methanol
	Nde	1-(4-Nitro-1,3-dioxoindan-2-ylidene) ethyl
	NHNde	NH-1-(4-nitro-1,3-dioxoindan-2-ylidene) ethyl
30	NMR	Nuclear magnetic resonance
	ODmab	4-{N-[1-(4,4-dimethyl-2,6-dioxocyclo-hexylidene)-3-methylbutyl]-amino}benzyl alcohol
	SPPS	solid phase peptide synthesis
	TBDMS	tert-butyl dimethyl silyl
35	tBu	tert-butyl
	Trt	trityl

The invention will now be described in detail by way of reference only to the following non-limiting examples, in which the structures of individual compounds are as summarised in the following tables.

Table 1




Compound No.	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	R ¹¹	R ¹²
1	OH/H	OH/H	NHDde	H	H	OH	OH	H	CH ₂ OH	H
2	H	AcO	NHDde	H	H	OAc	OAc	H	CH ₂ Oac	H
3	H	Br	NHDde	H	H	OAc	OAc	H	CH ₂ Oac	H
4	H/OMe	OMe/H	NHDde	H	H	OAc	OAc	H	CH ₂ Oac	H
5	Isothiouronium salt	H	NHDde	H	H	OAc	OAc	H	CH ₂ Oac	H
6	SMe	H	NHDde	H	H	OAc	OAc	H	CH ₂ Oac	H
7	H	OBn	NHDde	H	H	OH	OH	H	CH ₂ OH	H
8	N ₃	H	NHDde	H	H	OAc	Oac	H	CH ₂ Oac	H
9	SH	H	NHDde	H	H	OAc	Oac	H	CH ₂ Oac	H
10	H	OBn	NHDde	H	H	OH	Benzylidene	H	Benzylidene	H
11	H	OBn	NHDde	H	H	OAc	Oac	H	CH ₂ Oac	H
12	OH/H	H/OH	NHDde	H	H	OAc	Oac	H	CH ₂ Oac	H

Table 1 (continued)

Compound No.	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	R ¹¹	R ¹²
13	Imidate/H	H/Imidate	NHDde	H	H	OAc	OAc	H	CH ₂ OAc	H
14	H	OBn	NHDde	H	H	OH	OH	H	CH ₂ OTrt	H
15	H	OBn	NHDde	H	H	OH	OH	H	CH ₂ OTBDMs	H
16	NH ₂	H	NHDde	H	H	OAc	OAc	H	CH ₂ OAc	H
17	OAc	H	NHDde	H	H	OAc	OAc	H	CH ₂ Odmab	H
18	NH ₂	H	NHDde	H	H	OAc	OAc	H	CH ₂ OAc	H
19	NHDde	H	NHAc	H	H	OAc	OAc	H	CH ₂ OAc	H
20	H	OBn	NHDde	H	H	OH	Isopropylidene	H	Isopropylidene	H
21	H/OH	OH/H	NHDde	H	H	OH	H	OH	CH ₂ OH	H
22	H/OH	OH/H	NHNde	H	H	OH	OH	H	CH ₂ OH	H
23	H	OAc	NHNde	H	H	OAc	OAc	H	CH ₂ OAc	H

Table 2


*not in word*

5

10

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷
24	H	H	H	H	NHDde	CH ₂ OH	H

Table 3

*not in word*

15

20

Compound No.	R
25	N ₃
26	NH ₂
27	NHDde

25 Example 1 Synthesis of Dde protected aminosugars

2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxo-cyclohex-1-ylidene)ethylamino]-D-glucopyranose (1)

Sodium (143 mg, 6.21 mmol) was added to abs. methanol (30 ml) and the reaction mixture was stirred for 5 min. D-glucosamine hydrochloride (1.34 g, 6.21 mmol) was added to the resulting clear solution and the reaction

30

mixture was stirred at room temperature for another 5 min.
2- Acetyldimedone (1.69 g, 9.32 mmol) was added and the
reaction mixture was stirred under reflux for 5 hours. The
reaction mixture was cooled and the product was
5 precipitated by ether (200 ml) resulting in 2-Deoxy-2-[1-
(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-ethylamino]-D-
glucopyranose (1) (1.66 g, 77.9%).

R_f 0.37 (MeCN/H₂O 10:0.5);

10

FAB MS C₁₆H₂₅NO₇ (343.33) m/z (%) 366 [M+Na]⁺ (100), 268
(40), 246 (32), 224 (15).

¹H NMR (D₂O) δ 5.12 (d, H-1 g), 3.95-3.25 (m, 6H, sugar H),
15 2.38, 2.36 (2s, 3H, CH₃), 2.28, 2.27 (2s, 4H, 2 CH₂), 0.85
(s, 6H, 2 CH₃).

Example 2 Synthesis of Dde-protected O-acylated
aminosugars

20 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-
ethylamino]-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose (2)

A mixture of 2-deoxy-2-[1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)ethylamino]-D-glucopyranose
(1.55 g, 4.51 mmol), pyridine (11 ml) and acetic anhydride
25 (20 ml) was stirred at room temperature overnight. The
reaction mixture was evaporated, and the product was
crystallised from MeOH (10 ml) at -15°C to give 2-Deoxy-2-
[1-(4,4-dimethyl-2,6- dioxocyclohex-1-ylidene)ethyl-amino]-
1,3,4,6-tetra-O-acetyl-α-D-glucopyranose (2) (1.95 g, 86%).

30

R_f 0.35 (Hexane/EtOAc 1:1);

FAB MS C₂₄H₃₃NO₁₁ (511.50) m/z (%) 534 [M+Na]⁺ (20), 512
[M+H]⁺ (100), 452 (72), 338 (75).

35

¹H NMR (CDCl₃) δ 13.70 (d, 1H, NH), 6.22 (d, 1H, H-1,
J_{1,2}=3.66 Hz), 5.40 (t, 1H, H-3), 5.16 (t, 1H, H-4),

Example 4 Synthesis of Dde-protected O-alkylated
aminosugars

Methyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- β -D-glucopyranoside

5 (4)

2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- α -D-glucopyranosyl bromide (60 mg, 0.11 mmol) was dissolved in CH₂Cl₂ (5 ml), cooled to -15°C and silver trifluoro-methanesulphonate
10 (43 mg, 0.16 mmol) in MeOH (1 ml) added. The reaction mixture was stirred overnight, filtered and the filtrate evaporated. The residue was washed with saturated NaHCO₃ solution, dried over MgSO₄ and evaporated. The residue was
15 purified by chromatography, to give Methyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- β -D-glucopyranoside (4) (40 mg, 75%).

R_f 0.35 (Hexane/EtOAc 1:1);

20 FAB MS C₂₃H₃₃NO₁₀ (483.49) m/z (%) 506 [M+Na]⁺ (15), 484 [M+H]⁺ (100), 442 (8).

¹H NMR (CDCl₃) δ 13.84 (d, 1H, NH), 5.20 (t, 1H, H-3), 5.09 (t, 1H, H-4), 4.41 (d, 1H, H-1, J_{1,2}=8.29 Hz), 4.32
25 (dd, 1H, H-2), 4.14, 3.94 (2m, 2H, H-6), 3.75 (m, 1H, H-5), 3.48 (s, 3H, OCH₃), 2.57 (s, 3H, CH₃), 2.37 (s, 4H, 2 CH₂), 2.09, 2.03, 1.96 (3s, 9H, 3 AcO), 1.02 (s, 6H, 2 CH₃), and

Methyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- α -D-glucopyranoside
30 (4) (3 mg, 6%)

R_f 0.33 (Hexane/EtOAc 1:1);

35 FAB MS C₂₃H₃₃NO₁₀ (483.49) m/z (%) 506 [M+Na]⁺ (13), 484 [M+H]⁺ (100).

5 1.94 (3s, 9H, 3 AcO), 1.02 (s, 6H, 2 CH₃).

S-[2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-ethylamino]-3,4,6-tri-O-acetyl- β -D-glucopyranosyl]-isothiouronium bromide (5)

20 β -D-glucopyranosyl]isothiuronium bromide (5).

R_f 0.46 (CHCl₃/MeOH 5:1);

25 (100) .

30 1.96 (3s, 9H, 3 AcO), 1.02 (s, 6H, 2 CH₃).

Example 6 Synthesis of Dde-protected alkylthiolated
 aminosugars

Methyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio-3,4,6- tri-O-acetyl- β -D-glucopyranoside (6)

2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio-3,4,6-tri-O-acetyl- β -D-glucopyranose (72 mg, 0.148 mmol) was dissolved in acetone (0.15 ml) and K_2CO_3 (23 mg) in water (0.15 ml) added. The reaction mixture was stirred under N_2 at room temperature and methyl iodide (23 mg, 0.163 mmol) added. After 30 min stirring the reaction mixture was concentrated under reduced pressure. CH_2Cl_2 (2ml) was added to the reaction mixture and the layers were separated. The organic phase was washed with water (0.5 ml), dried over $MgSO_4$ and evaporated. The residue was purified by chromatography using EtOAc/hexane 3:1 to give Methyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-thio-3,4,6-tri-O-acetyl- β -D-glucopyranoside (6) (50 mg, 67%).

R_f 0.41 (EtOAc/hexane 3:1);

FAB MS $C_{23}H_{33}NO_9S$ (499.49) m/z (%) 522 $[M+Na]^+$ (25), 500 $[M+H]^+$ (100), 452 (27), 338 (35).

¹H NMR (CDCl₃) δ 13.96 (d, 1H, NH), 5.22 (t, 1H, H-3), 5.13 (t, 1H, H-4), 4.61 (d, 1H, H-1, J_{1,2}=9.98 Hz), 4.30 (dd, 1H, H-2), 4.15 (m, 2H, H-6', H-5), 2.60 (s, 3H, CH₃), 2.42 (s, 4H, 2 CH₂), 2.20 (s, 3H, SCH₃), 2.09, 2.02, 1.96 (3s, 9H, 3 AcO), 1.03 (s, 6H, 2 CH₃).

Example 7 Synthesis of Dde-protected benzylated
 aminosugars

Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]- α -D- glucopyranoside (7)

A solution of Benzyl 2-Acetamido-2-deoxy- α -D-glucopyranoside (4.70 g, 15.11 mmol) in 1 M NaOH solution

was refluxed at 120°C for 15 h. The reaction mixture was cooled to room temperature, neutralised with 1 M HCl solution and concentrated. The residue was dissolved in dry EtOH (50 ml) and filtered. 2-Acetyldimedone (4.11 g, 22.6 mmol) and N,N-diisopropylethylamine (2 ml) were added to the filtrate, and the mixture was refluxed for 2 h. The reaction mixture was evaporated to dryness, and the residue was taken up in EtOAc (50 ml), washed with 1M KHSO₄ solution, brine, and evaporated to give Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]- α -D-glucopyranoside (7) (3.78 g, 58%).

R_f 0.43 (CH₂Cl₂/EtOAc/MeOH 10:7:3);

FAB MS C₂₃H₃₁NO₇ (433.48) m/z (%) 456 [M+Na]⁺ (45), 434 [M+H]⁺ (100), 452 (30), 338 (25)..

¹H NMR (CDCl₃) δ 13.44 (d, 1H, NH), 7.33 - 7.21 (m, 5H, 5 Ar-H), 4.80 (d, 1H, H-1, J_{1,2}=3.45 Hz), 4.71, 4.56 (2d, 2H, CH₂Ar), 2.45 (s, 3H, CH₃), 2.31 (s, 4H, 2 CH₂), 0.99 (s, 6H, 2 CH₃).

Example 8 Synthesis of Dde-protected azido derivative of aminosugars

2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- β -D-glucopyranosyl azide (8)

A mixture of 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O- α -D-glucopyranosyl bromide (100 mg, 0.18 mmol), sodium azide (100 mg, 1.56 mmol) in DMF (5 ml) was stirred at 80°C for 2 hours. The reaction mixture was evaporated, taken up in CH₂Cl₂ (10 ml), washed with H₂O (2 x 2 ml), dried over MgSO₄ and concentrated. The residue was purified by chromatography, using hexane/EtOAc 1:1 as the mobile phase, to give 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- β -D-glucopyranosyl azide (8) (65 mg, 70%).

R_f 0.55 (hexane/EtOAc 1:1);

FAB MS C₂₂H₃₀N₄O₉ (494.48) m/z (%) 517 [M+Na]⁺ (15), 495
5 [M+H]⁺ (100), 452 (10), 338 (25).

¹H NMR (CDCl₃) δ 13.91 (d, 1H, NH), 5.19 (t, 1H, H-3),
5.10 (t, 1H, H-4), 4.87 (d, 1H, H-1, J_{1,2}=8.95 Hz),
4.34 (dd, 1H, H-2), 4.15 (dd, 1H, H-6'), 3.85 (m, 2H, H-5,
10 H-6), 2.59 (s, 3H, CH₃), 2.38 (s, 4H, 2 CH₂), 1.02 (s, 6H,
2 CH₃).

Example 9 Synthesis of Dde-protected thiolated
 aminosugars

15 2-Deoxy-2-[1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-
ethylamino]-1-thio-3,4,6-tri-O-acetyl-β-D-glucopyranose
(9)

To S-[2-Deoxy-2-[1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl-β-D-
20 glucopyranosyl]isothiuronium bromide (136 mg, 0.22 mmol) a
solution of Na₂S₂O₅ (43 mg, 0.225 mmol) in water (0.2 ml)
and 1,2-dichloroethane (0.24 ml) was added. The reaction
mixture was kept under reflux at 85°C for 20 min. After
dilution with CH₂Cl₂ (5 ml), the layers were separated, the
25 organic phase was washed with water (3 ml), dried over
MgSO₄, concentrated under reduced pressure, and
chromatographed using ether /MeOH 10:1 to give 2-Deoxy-2-
[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-1-
thio-3,4,6-tri-O-acetyl-β-D-glucopyranose (9) (95 mg, 87%).

30

R_f 0.31 (ether/MeOH 10:1);

FAB MS C₂₂H₃₁NO₉S (485.47) m/z (%) 508 [M+Na]⁺ (15),
486 [M+H]⁺ (100), 452 (33), 338 (20).

35

¹H NMR (CDCl₃) δ 13.97 (d, 1H, NH), 5.32 (t, 1H, H-3),
5.15 (t, 1H, H-4), 4.75 (dd, 1H, H-1, J_{1,2}=8.29 Hz),

3.85 (m, 1H, H-5), 2.62 (s, 3H, CH₃), 2.38 (s, 4H, 2 CH₂), 2.10, 2.04, 1.96 (3s, 9H, 3 AcO), 1.02 (s, 6H, 2 CH₃).

Example 10 Synthesis of Dde-protected benzylidene derivative of aminosugars

Benzyl 4,6-O-Benzylidene-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]- α -D-glucopyranoside (10)

A mixture of benzaldehyde (1 ml), formic acid (1 ml) and Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]- α -D-glucopyranoside (433 mg, 1 mmol) was stirred at room temperature for 2 h. The reaction mixture was evaporated to dryness using a high vacuum rotary evaporator. The residue was treated with ether (40 ml) and the suspension filtered. The solid purified by chromatography, using CHCl₃-EtOAc 10:4 as the mobile phase, to give Benzyl 4,6-O-Benzylidene-2-deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-ethylamino]- α -D-glucopyranoside (10) (340 mg, 65%).

R_f0.38 (CHCl₃-EtOAc 10:4);

FAB MS C₃₀H₃₅NO₇ (521.58) m/z (%) 544 [M+Na]⁺ (10), 522 [M+H]⁺ (100), 338 (40).

¹H NMR (CDCl₃) δ 13.52 (d, 1H, NH), 7.37 - 7.26 (m, 10H, 10 Ar-H), 5.56 (s, 1H, CH-Ar), 4.90, 4.60 (2d, 2H, CH₂-Ar), 4.79 (d, 1H, H-1, J_{1,2}=3.08 Hz), 4.35 (t, 1H, H-4), 4.26 (dd, 1H, H-2), 3.98 (m, 2H, H-5, H-3), 3.77 (t, 1H, H-6'), 3.63 (t, 1H, H-6), 2.57 (s, 3H, CH₃), 2.33 (s, 4H, 2 CH₂), 1.01 (s, 6H, 2 CH₃).

Example 11 Synthesis of Dde - protected reducing
aminosugars

2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-
ethylamino]-3,4,6-tri-O-acetyl- α -D-glucopyranose (12)

5 Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)ethylamino]- α -D-glucopyranoside
(400 mg, 0.92 mmol) was dissolved in pyridine (6 ml) and
cooled to 0°C, then acetic anhydride (10 ml) was added
dropwise. The solution was stirred at room temperature
10 overnight, then evaporated. The residue was purified by
chromatography using EtOAc/hexane 3:1 to give Benzyl 2-
Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-
ethylamino]-3,4,6-tri-O-acetyl- α -D-glucopyranoside (11)
(465 mg, 90%).

15

R_f 0.41 (EtOAc/hexane 3:1);

FAB MS C₂₉H₃₇NO₁₀ (559.59) m/z (%) 532 [M+Na]⁺ (15),
560 [M+H]⁺ (100), 452 (20), 338 (55).

20

¹H NMR (CDCl₃) δ 13.66 (d, 1H, NH), 7.43 - 7.32 (m, 5H,
5 Ar-H), 5.45 (t, 1H, H-3), 5.07 (t, 1H, H-4), 4.93 (d, 1H,
H-1, J_{1,2}=3.53 Hz), 4.76, 4.72 (2d, 2H, CH₂-Ar), 4.29 (dd,
1H, H-2), 4.07 (m, 2H, H-6', H-5), 3.96 (dd, 1H, H-6),
25 2.52 (s, 3H, CH₃), 2.38 (s, 4H, 2 CH₂), 2.10, 2.00,
1.94 (3s, 9H, 3 AcO), 1.03 (s, 6H, 2 CH₃).

30 Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxo-
cyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- α -D-
glucopyranoside (11) (100 mg, 0.17 mmol) was dissolved in
MeOH (5 ml) and hydrogenated over Pd/C (10%) (20 mg)
overnight. The suspension was filtered, and the filtrate
was evaporated to give 2-Deoxy-2-[1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- α -D-
35 glucopyranose (12) (75 mg, 90%).

R_f 0.44 (CHCl₃/EtOAc 1:1);

FAB MS $C_{22}H_{31}NO_{10}$ (469.47) m/z (%) 492 $[M+Na]^+$ (45),
470 $[M+H]^+$ (100), 452 (10).

- 5 1H NMR ($CDCl_3$) δ 13.81 (d, 1H, NH), 5.49 (t, 1H, H-3),
5.28 (d, 1H, H-1, $J_{1,2}=3.29$ Hz), 5.11 (t, 1H, H-4),
4.42 (dd, H, H-2), 4.33 (dd, H, H-6'), 2.59 (s, 3H, CH_3),
2.37 (s, 4H, 2 CH_2), 2.10, 2.03, 1.96 (3s, 9H, 3 AcO),
1.01 (s, 6H, 2 CH_3).

10

Example 12 Synthesis of Dde-protected
 trichloroacetimidate of aminosugars

2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-
ethylamino]-3,4,6-tri-O-acetyl- α,β -D-glucopyranosyl

- 15 trichloroacetimidate (13)

A mixture of 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- α -D-glucopyranose (100 mg, 0.21 mmol) and trichloroacetonitrile in CH_2Cl_2 was cooled to 0°C and 1,8-diazabicyclo(5.4.0)-
20 undec-7-en (2 mg) added. The reaction mixture was stirred at 0°C for 1.5 h and at room temperature for 2 h. The solution was evaporated, and the residue chromatographed using $CHCl_3$ /EtOAc 1:1 as the mobile phase to give 2-deoxy-
2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-
25 3,4,6-tri-O-acetyl- α,β -D-glucopyranosyl trichloroacetimidate (13) (71 mg, 55%).

R_f 0.61 ($CHCl_3$ /EtOAc 1:1);

- 30 FAB MS $C_{24}H_{31}Cl_3N_2O_{10}$ (613.88) m/z (%) 635 $[M+Na]^+$ (75),
452 (100).

- 1H NMR ($CDCl_3$) δ 13.95, 13.72 (2d, 1H, $NH_{A,B}$), 8.84,
8.76 (2s, 1H, $NH_{A,B}$), 6.48 (d, H-1 $_{\alpha}$, $J_{1,2}=3.05$ Hz),
35 5.85 (d, H-1 $_{\beta}$, $J_{1,2}=8.72$ Hz), 5.52 (t, 1H, H-3), 5.31 (t,
1H, H-4), 2.65, 2.63 (2s, 3H, $CH_3_{\alpha,\beta}$), 2.31 (2s, 4H,

2 CH₂ α , β), 2.09, 2.08, 2.05, 2.04, 1.99, 1.97 (6s, 9H,
3 AcO α , β), 0.99, 0.98 (2s, 6H, 2 CH₃ α , β).

Example 13 Synthesis of Dde-protected

5 O-triphenylmethylated aminosugars

Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-6-O-triphenylmethyl- α -D-glucopyranoside (14)

10 A mixture of Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]- α -D-glucopyranoside (100 mg, 0.23 mmol), triphenylmethylbromide (149 mg, 0.46 mmol) in DMF/pyridine 1:1 (2 ml) was stirred at 100°C for 15 h. The reaction mixture was evaporated, the residue was taken up in CHCl₃ (10 ml), washed with water (3 ml),
15 dried over MgSO₄ and concentrated. The residue was purified by chromatography using CHCl₃/MeOH 10:1 as the mobile phase to give Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-6-O-triphenylmethyl- α -D-glucopyranoside (14) (104 mg, 64%).

20

R_f 0.55 (CHCl₃/MeOH 10:1);

FAB MS C₄₂H₄₅NO₇ (675.68) m/z (%) 698 [M+Na]⁺ (40), 676 [M+H]⁺ (100).

25

¹H NMR (CDCl₃) δ 13.49 (d, 1H, NH), 7.49 - 7.23 (m, 20H, 20 Ar-H), 4.87, 4.66 (2d, 2H, CH₂Ar), 4.83 (d, 1H, H-1, J_{1,2}=3.70 Hz), 3.84 (t, 1H, H-3), 2.55 (s, 3H, CH₃), 2.31 (s, 4H, 2 CH₂), 1.02 (s, 6H, 2 CH₃).

30

Example 14 Synthesis of Dde-protected O-silylated
aminosugars

Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-6-O-t-butyltrimethylsilyl- α -D-glucopyranoside (15)

35

Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]- α -D-glucopyranoside

(100 mg, 0.23 mmol) was dissolved in dry pyridine (2 ml), cooled to 0°C and t-butyldimethylsilylchloride (39 mg, 0.26 mmol) added. The reaction mixture was stirred at room temperature overnight. The solution was evaporated, the residue was taken up in CHCl₃ (10 ml), washed with water (3 ml), dried over MgSO₄ and concentrated. The residue was purified by chromatography using CHCl₃/MeOH 10:1 as the mobile phase to give Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-6-O-t-butyldimethylsilyl- α -D-glucopyranoside (15) (77 mg, 61%).

R_f 0.57 (CHCl₃/MeOH 10:1);

FAB MS C₂₉H₄₅NO₇Si (547.74) m/z (%) 570 [M+Na]⁺ (10),
548 [M+H]⁺ (100).

¹H NMR (CDCl₃) δ 13.45 (d, 1H, NH), 7.40-7.27 (m, 5H, 5 Ar-H), 4.88, 4.65 (2d, 2H, CH₂Ar), 4.79 (d, 1H, H-1, J_{1,2}=3.42 Hz), 2.55 (s, 3H, CH₃), 2.31 (s, 4H, 2 CH₂), 1.02 (s, 6H, 2 CH₃), 0.93 (s, 9H, 3 CH₃), 0.10 (s, 6H, 2 CH₃Si).

Example 15 Synthesis of partially protected polyaminosugars

2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- β -D-glucopyranosyl amine (16)

2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- β -D-glucopyranosyl amine (60 mg, 0.12 mmol) was dissolved in MeOH (5 ml) and hydrogenated over Pd/C (10%) (10 mg) overnight. The suspension was filtered, the filtrate was evaporated to give 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-3,4,6-tri-O-acetyl- β -D-glucopyranosyl amine (16) (45 mg, 80%).

R_f 0.38 (EtOAc);

FAB MS $C_{22}H_{32}N_2O_9$ (468.50) m/z (%) 491 $[M+Na]^+$ (100),
469 $[M+H]^+$ (25), 452 (10).

- 5 1H NMR ($CDCl_3$) δ 13.75 (d, 1H, NH), 2.61 (s, 3H, CH_3),
2.35 (s, 4H, 2 CH_2), 2.09, 2.02, 1.98 (3s, 9H, 3 AcO),
1.03 (s, 6H, 2 CH_3).

Example 16 Synthesis of Dmab-protected sugars

- 10 4-[N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-ethyl]-
amino]benzyl (1,2,3,4-tetra-O-acetyl- β -D-glucopyranose)-
uronate (17)

- A mixture of 1,2,3,4-tetra-O-acetyl- β -D-glucuronic acid (100 mg, 0.27 mmol), 4-[N-[1-(4,4-dimethyl-
15 2,6-dioxocyclohexylidene)ethyl]amino]benzyl alcohol (79 mg,
0.27 mmol), 1,3-dicyclohexylcarbodiimide (62 mg,
0.30 mmol) in CH_2Cl_2 was stirred overnight at room
temperature. The reaction mixture was evaporated, the
residue was purified by chromatography using $CHCl_3/EtOAc$
20 10:4 to give 4-[N-[1-(4,4-dimethyl-2,6-dioxocyclohexyl-
idene)ethyl]-amino]benzyl (1,2,3,4-tetra-O-acetyl- β -D-
glucopyranose)uronate (17) (92 mg, 53%).

R_f 0.51 ($CHCl_3/EtOAc$ 10:4);

25

FAB MS $C_{31}H_{37}NO_{13}$ (631.61) m/z (%) 654 $[M+Na]^+$ (10),
632 $[M+H]^+$ (35), 270 (100).

- 30 1H NMR ($CDCl_3$) δ 15.06 (d, 1H, NH), 7.41 (d, 2H, 2 Ar-H),
7.15 (d, 2H, 2 Ar-H), 5.76 (d, 1H, H-1, $J_{1,2}=9.08$ Hz),
4.22 (d, 1H, H-5, $J_{1,2}=9.36$ Hz), 2.51 (s, 3H, CH_3),
2.37 (s, 4H, 2 CH_2), 2.09, 2.00, 1.86 (3s, 9H, 3 AcO),
1.07 (s, 6H, 2 CH_3).

Example 17 Synthesis of Dde- and N-acyl-protected
polyaminosugars

2-Acetamido-3,4,6-tri-O-acetyl-1,2-dideoxy-1-[1-(4,4-
dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]- β -D-
5 glucopyranose (19)

2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl- β -D-
glucopyranosyl azide (100 mg, 0.26 mmol) was dissolved in
MeOH (5 ml) and hydrogenated over Pd/C (10%) (10 mg) for
5 h. The suspension was filtered, and the filtrate was
10 evaporated to give 2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-
 β -D-glucopyranosyl amine (18) (80 mg, 86%).

R_f 0.38 (CHCl₃/MeOH 10:1);

15 FAB MS C₁₄H₂₂N₂O₈ (346.34) m/z (%) 347 [M+H]⁺ (100),
330 (25).

¹H NMR (CDCl₃) δ 5.64 (d, 1H, NH), 3.99 (m, 1H, H-2),
3.65 (m, 1H, H-5), 2.11, 2.04, 2.02, 1.97 (4s, 12H, 3 AcO,
20 AcNH).

A mixture of 2-Acetamido-2-deoxy-3,4,6-tri-O-
acetyl- β -D-glucopyranosyl amine (80 mg, 0.23 mmol) and
2-acetyldimedone (55 mg, 0.30 mmol) in MeOH (5 ml) was
25 refluxed for 5 h. The reaction mixture was evaporated, the
residue was purified by chromatography using CHCl₃/MeOH
10:0.5 as the mobile phase, to give 2-Acetamido-3,4,6-tri-
O-acetyl-1,2-dideoxy-1-[1-(4,4-dimethyl-2,6-dioxocyclohex-
1-ylidene)ethylamino]- β -D-glucopyranose (19) (70 mg, 60%).

30

R_f 0.37 (CHCl₃/MeOH 10:0.5);

FAB MS C₂₄H₃₄N₂O₁₀ (510.53) m/z (%) 533 [M+Na]⁺ (80),
511 [M+H]⁺ (100), 330 (25).

35

¹H NMR (CDCl₃) δ 13.60 (d, 1H, NH), 5.81 (d, 1H, NH),
5.45 (t, 1H, H-3), 5.31 (m, 1H, H-1), 5.05 (t, 1H, H-4),

4.21 (dd, 1H, H-6'), 4.11 (dd, 1H, H-6), 3.92 (m, 1H, H-2), 3.82 (m, 1H, H-5), 2.58 (s, 3H, CH₃), 2.35 (s, 4H, 2 CH₂), 2.06, 2.04, 2.02, 1.92 (3s, 9H, 2 AcO, AcNH), 1.01 (s, 6H, 2 CH₃).

5

Example 18 Synthesis of Dde-protected O-isopropylidene derivative of aminosugars

Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-4,6-O-isopropylidene- α -D-

10 glucopyranoside (20)

A mixture of Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]- α -D-glucopyranoside (100 mg, 0.23 mmol) and (+/-)-10-camphorsulphonic acid (5 mg) in 2,2-dimethoxypropane (10 ml) was refluxed for 2 h.

15 The reaction mixture was evaporated, and the residue was taken up in CH₂Cl₂ (10 ml), washed with saturated NaHCO₃ solution (3 ml), and concentrated. The residue was purified by chromatography using CH₂Cl₂/MeOH 10:1 as the mobile phase to give Benzyl 2-Deoxy-2-[1-(4,4-dimethyl-2,6-

20 dioxocyclohex-1-ylidene)ethylamino]-4,6-O-isopropylidene- α -D-glucopyranoside (20) (82 mg, 75%).

R_f 0.44 (CH₂Cl₂/MeOH 10:1);

25 FAB MS C₂₆H₃₅NO₇ (473.54) m/z (%) 496 [M+Na]⁺ (20), 474 [M+H]⁺ (100), 382 (15).

¹H NMR (CDCl₃) δ 13.48 (d, 1H, NH), 7.38 - 7.27 (m, 5H, 5 Ar-H), 4.97, 4.65 (2d, 2H, CH₂Ar), 4.76 (d, 1H, H-1, J_{1,2}=3.55 Hz), 2.55 (s, 3H, CH₃), 2.31 (s, 4H, 2 CH₂), 1.52, 1.30 (2s, 6H, 2 CH₃), 1.00 (s, 6H, 2 CH₃).

30

Example 19 Synthesis of Dde- protected galacto-aminosugars

2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-ethylamino]-D-galactopyranose (21)

- 5 Sodium (22 mg, 0.95 mmol) was added to abs. methanol (10 ml) and the reaction mixture was stirred for 5 min. D-galactosamine hydrochloride (206 mg, 0.95 mmol) was added to the resulting clear solution, and the reaction mixture was stirred at room temperature for another 5 min.
- 10 2-Acetyldimedone (261 mg, 1.43 mmol) was added and the reaction mixture was stirred under reflux for 5 hours. The solution was cooled and the product was precipitated by ether (100 ml) resulting in 2-Deoxy-2-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethylamino]-D-galactopyranose (21)
- 15 (270 mg, 75%).

R_f 0.37 (MeCN/H₂O 10:0.5);

- FAB MS C₁₆H₂₅NO₇ (343.33) m/z (%) 366 [M+Na]⁺ (40), 344
- 20 [M+H]⁺ (100), 327 (30).

- ¹H NMR (D₂O) δ 5.34 (d, H-1_A, J_{1,2} = 3.54 Hz), 4.87 (d, H-1_B), 4.28 (dd, H-2_α), 4.17 (t, H-2_β), 4.08 (d, H-4_α), 4.03 (d, H-4_β), 2.56 (s, 3H, CH₃), 2.48, 2.44 (2s, 4H, 2
- 25 CH₂), 1.03 (s, 6H, 2 CH₃).

Example 20 Synthesis of Nde-protected aminosugars

2-Deoxy-2-[1-(4-nitro-1,3-dioxoindan-2-ylidene)-ethylamino]-D-glucopyranose (22)

- 30 Sodium (126 mg, 5.47 mmol) was added to abs. methanol (50 ml) and the reaction mixture was stirred for 5 min. D-glucosamine hydrochloride (1.18 g, 5.47 mmol) was added to the resulting clear solution and the reaction mixture was stirred at room temperature for another 5 min.
- 35 2-acetyl-4-nitroindane-1,3-dione (1.91 g, 8.21 mmol) was added and the reaction mixture was stirred under reflux for 5 hours. The solution was cooled and the product was

filtered off. The solid was washed with MeOH (10 ml), ether (50 ml) and dried, affording 2-Deoxy-2-[1-(4-nitro-1,3-dioxoindan-2-ylidene)ethylamino]-D-glucopyranose (22) (1.10 g, 55%).

5

R_f 0.41 (MeCN/H₂O 10:0.5);

FAB MS C₁₇H₁₈N₂O₉ (394.32) m/z (%) 395 [M+H]⁺ (100).

10 ¹H NMR (D₂O) δ 7.75-7.40 (m, 3H, 3 Ar-H), 5.21 (d, H-1_α), 3.95-3.25 (sugar 6H), 3.18 (s, 3H, CH₃).

Example 21 Synthesis of Nde - protected O-acetylated
aminosugars

15 2-Deoxy-2-[1-(4-nitro-1,3-dioxoindan-2-ylidene)-ethylamino]-3,4,6-tri-O-acetyl-α-D-glucopyranose (23)

A mixture of 2-Deoxy-2-[1-(4-nitro-1,3-dioxoindan-2-ylidene)ethylamino]-D-glucopyranose (100 mg, 0.23 mmol), pyridine (2 ml) and acetic anhydride (3 ml)
20 stirred at room temperature overnight. The reaction mixture was evaporated, and the residue was purified by chromatography using CHCl₃/EtOAc 10:4 as the mobile phase to give 2-Deoxy-2-[1-(4-nitro-1,3-dioxoindan-2-ylidene)-ethylamino]-3,4,6-tri-O-acetyl-α-D-glucopyranose (23)
25 (165 mg, 79%).

FAB MS C₂₅H₂₆N₂O₁₃ (562.48) m/z (%) 585 [M+Na]⁺ (40), 563 [M+H]⁺ (100), 503 (45).

30 ¹H NMR (CDCl₃) δ 11.00, 10.90 (2d, 1H, NH_{E,Z}), 7.95-7.68 (m, 3H, 3 Ar-H), 6.25, 6.24 (2d, 1H, H-1_{E,Z}), 5.43 (t, 1H, H-3), 5.18 (t, 1H, H-4), 2.68 (s, 3H, CH₃), 2.38, 2.07, 2.04, 2.00 (4s, 12H, 4 AcO).

Example 22 Synthesis of Dde-protected deoxyaminosugars
with furanose ring

3'-deoxy-3'-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-ethylamino]-thymidine (24)

- 5 3'-Deoxy-3'-azido-thymidine (200 mg, 0.75 mmol) was dissolved in MeOH (25 ml) and Pd/C (40 mg) was added. The suspension was stirred over a constant stream of H₂ overnight. The reaction mixture was filtered, and the filtrate was concentrated. The residue was taken up in
10 abs. EtOH (5 ml), N,N-diisopropylethylamine (0.1 ml) and 2-acetyldimedone (204 mg, 1.12 mmol) were added and the solution was refluxed for 5 h. The reaction mixture was cooled to room temperature and the product was precipitated by adding ether (50 ml) giving 3'-deoxy-3'-[1-(4,4-
15 dimethyl-2,6-dioxocyclohex-1-ylidene)-ethylamino]-thymidine (24) (200 mg, 66%).

R_f 0.45 (CH₂Cl₂/EtOAc/MeOH 10:7:3);

- 20 FAB MS C₂₀H₂₇N₃O₄ (405.45) m/z (%) 428 [M+Na]⁺ (55), 406 [M+H]⁺ (100).

- ¹H NMR (CDCl₃) δ 13.79 (d, 1H, NH), 7.55 (s, 1H, H-6), 6.13 (m, 1H, H-1'), 4.70 (m, 1H, H-5'), 4.04 (m, 1H, H-3'),
25 3.96 (dd, 1H, H-5'_a), 3.72 (dd, 1H, H-5'_b), 2.55 (s, 3H, CH₃), 2.42 (m, 1H, H-2'_a), 2.32 (s, 4H, 2 CH₂), 1.80 (s, 3H, CH₃), 0.96 (s, 6H, 2 CH₃).

Example 23 Synthesis of Dde-protected aminosugar
30 containing oligosaccharides

4-O-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)-2,3,6-tri-O-acetyl-N-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl]-β-D-glucopyranosyl amine (27)

- 35 A mixture of β-lactose octaacetate (203 mg, 0.3 mmol), trimethylsilyl azide (41 mg, 0.35 mmol), and SnCl₄ (40 mg, 0.15 mmol) in CH₂Cl₂ (1.5 ml) was stirred overnight at room temperature. The solution was diluted

with CH₂Cl₂ (20 ml) and washed twice with 1 M potassium fluoride solution (5 ml), water (5 ml) and evaporated affording 4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)-2,3,6-tri-O-acetyl- β -D-glucopyranosyl azide (25) (178 mg 90%).

R_f 0.38 (hexane/EtOAc 1:1);

FAB MS C₂₆H₃₅N₃O₁₇ (661.56) m/z (%) 684 [M+Na]⁺ (70), 662 [M+H]⁺ (20), 331 (100).

¹H NMR (CDCl₃) δ 5.35 (d, 1H, H-4'), 4.95 (d, 1H, H-1', J_{1,2}=3.63 Hz), 4.61 (d, 1H, H-1, J_{1,2}=9.13 Hz), 2.14, 2.13, 2.07, 2.06, 2.04, 1.96 (6s, 21H, 7 AcO).

4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)-2,3,6-tri-O-acetyl- β -D-glucopyranosyl azide (178 mg, 0.26 mmol) was dissolved in MeOH (5 ml) and hydrogenated over Pd/C (10%) (10 mg) for 5 h. The suspension was filtered, and the filtrate was evaporated to give 4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)-2,3,6-tri-O-acetyl- β -D-glucopyranosyl amine (26) (157 mg, 92%).

R_f 0.41 (EtOAc);

FAB MS C₂₆H₃₇NO₁₇ (635.56) m/z (%) 658 [M+Na]⁺ (35), 636 [M+H]⁺ (40), 331 (100).

¹H NMR (CDCl₃) δ 5.35 (d, 1H, H-4'), 2.15, 2.12, 2.07, 2.06, 2.04, 2.03, 1.96 (7s, 21H, 7 AcO).

A mixture of 4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)-2,3,6-tri-O-acetyl- β -D-glucopyranosyl amine (157 mg, 0.24 mmol) and 2-acetyldimedone (81 mg, 0.45 mmol) in MeOH (5 ml) was refluxed for 5 h. The reaction mixture was evaporated, and the residue was purified by

chromatography using $\text{CHCl}_3/\text{EtOAc}$ 1:1 as the mobile phase, to give 4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)-2,3,6-tri-O-acetyl-N-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl]- β -D-glucopyranosyl amine (27) (106 mg, 54%).

5

R_f 0.39 ($\text{CHCl}_3/\text{EtOAc}$ 1:1);

FAB MS $\text{C}_{36}\text{H}_{49}\text{NO}_{19}$ (799.75) m/z (%) 822 $[\text{M}+\text{Na}]^+$ (50), 800 $[\text{M}+\text{H}]^+$ (100).

10

^1H NMR (CDCl_3) δ 13.56 (d, 1H, NH), 5.35 (d, 1H, H-1', $J_{1,2}=3.13$ Hz), 2.60 (s, 3H, CH_3), 2.36 (s, 4H, 2 CH_2), 2.15, 2.12, 2.07, 2.06, 2.04, 2.03, 1.96 (7s, 21H, 7 AcO), 1.02 (s, 6H, 2 CH_3).

15

Example 24 Synthesis of 2-Acetyl-4-nitroindan-1,3-dione
2-Acetyl-4-nitroindan-1,3-dione

A mixture of 3-nitrophthalic anhydride (12 g, 60 mmol), anhydrous pyridine (25 ml), piperidine (0.2 ml) and 2,4-pentanedione (6.25 g, 60 mmol) was stirred at 40°C for 6 h. The reaction mixture was cooled to 0°C and the crystalline mass was collected at the pump, washed with ether, and dried to give the yellow pyridinium salt. The salt was treated with 6 M HCl (100 ml) and the solid was filtered off. The product was crystallised from isopropanol to afford 2-Acetyl-4-nitroindan-1,3-dione (8.74g, 79%).

25

R_f 0.44 (EtOAc/AcOH 100:0.2);

30

FAB MS $\text{C}_{11}\text{H}_7\text{NO}_5$ (233.17) m/z (%) 256 $[\text{M}+\text{Na}]^+$ (20), 234 $[\text{M}+\text{H}]^+$ (100).

^1H NMR (CDCl_3) δ 8.09 -7.83 (m, 3H, 3 Ar- H(E,Z)), 2.62, 2.60 (2s, 3H, CH_3 (E,Z)).

35

It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments
5 and methods described herein may be made without departing from the scope of the inventive concept disclosed in this invention.

References cited herein are listed on the
10 following pages, and are incorporated by this reference.


REFERENCES

- Boullanger, P., Banoub, J. and Descotes, G.
Can. J. Chem., 1987 65 1343.
- 5 Bovin, N.V., Zurabyan, S.E. and Khorlin, A.Y.
Carbohydr. Chem., 1986 5 215.
- Buskas, T., Garegg, P.J., Konvadsson, P. and
10 Maloisel, J.L.
Tetrahedron Asymmetry, 1994 5 2187.
- Bycroft, B.W., Chan, W.C., Chhabra, S.R. and Hone, N.D.
J. Chem. Soc. Chem. Commun., 1993 778.
- 15 Castro-Palomino, J.C. and Schmidt, R.R.
Tetrahedron Lett., 1995 36 5343.
- Chan, W.C., Bycroft, B.W., Evans, D.J. and White, P.D.
20 J. Chem. Soc. Chem. Commun., 1995 2209.
- Dasgupta, F. and Garegg, P.J.
J. Chem. Soc. Chem. Commun., 1989 1640
- 25 Fields, G.B. and Noble, R.L.
Int. J. Peptide Protein Res., 1990 35 161.
- Griffith, D.A. and Danishefsky, S.J.
J. Am. Chem. Soc., 1990 112 5811.
- 30 Hayakawa, Y., Kato, H., Uchiyama, M., Kajino, H. and
Noyori, R.
J. Org. Chem., 1986 51 2400.
- 35 Imoto, M., Yoshimura, H., Shimamoto, T., Sakahuchi, N.,
Kusumoto, S. and Shiba, T.
Bull. Chem. Soc. Jpn., 1987 60 2205.


- Kaifu, R. and Osawa, T.
Carbohydr. Res., 1977 58 235.
- 5 Lemieux, R.V., Abbas, S.Z. and Chung, B.Y.
Can. J. Chem., 1982 60 58.
- Lemieux, R.V. and Ratcliffe, R.T.
Can. J. Chem., 1979 57 1244.
- 10 Mootoo, D.R. and Fraser-Reid, B.
Tetrahedron Lett., 1989 30 2363.
- Palsen, H.
15 Angew. Chem. Int. Ed. Engl., 1982 21 155.
- Paulsen, H. and Stenzel, W.,
Chem. Ber., 1978 111 2334 & 2348.
- 20 Sasaki, T., Minamoto, K. and Itoh, H.
J. Org. Chem., 1978 43 2320.
- Schmidt, R.R. and Kinzy, W
Adv. Carbohydr. Chem. Biochem., 1994 50 21-121.
- 25 Shapiro, D., Acher, A.J. and Rachaman, E.S.
J. Org. Chem., 1967 32 3767.
- Tailler, D., Jacquiaet, J.C., Noirot, A.M. and
30 Bean, J.M.
J. Chem. Soc., Perkin. Trans. I, 1992 3163.
- Toyokuni, T. and Singhal, A.K.
Chem. Soc. Rev., 1995, 231.
- 35 Zurabyan, S.E., Antenenko, T.S. and Khorlin, A.Y.
Carbohydr. Res., 1994 50 21-121

CLAIMS:

1. A compound containing a sugar carrying one or more primary amine groups protected with a 2-substituted-1,3-dioxo compound of General Formula I or General
5 Formula II:



I



II

10 in which

R^1 and R^2 may be the same or different, and is each hydrogen or C_{1-4} alkyl,


R' is an amino sugar, a glycosylamine, or an oligosaccharide comprising at least one aminosugar or one
15 glycosylamine unit, in which the sugar is coupled via an amino group,

and R'' is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl or substituted cycloalkyl.


2. A compound according to Claim 1, in which the
20 protecting group is of General Formula I and R^1 and R^2 are both methyl.

3. A compound according to Claim 1, selected from the group consisting of Compounds 1 to 23 as described in Table 1, Compound 24 as described in Table 2 and compounds
25 25 to 27 as described in Table 3.

4. A reagent for solution phase synthesis of sugar-containing compounds, comprising a cyclic 2-substituted-1,3-dioxo compound of General Formula I or General
Formula II



I



II

in which


- 5 R^1 and R^2 may be the same or different, and is each hydrogen or C_{1-4} alkyl,

R' is an amino sugar, a glycosylamine, or an oligosaccharide comprising at least one aminosugar or one glycosylamine unit, in which the sugar is coupled via an amino group,


and R'' is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl or substituted cycloalkyl.

5. A reagent according to Claim 4 in which the protecting group is of General Formula I and both R^1 and R^2 are methyl.

6. A linker-saccharide complex, comprising a linker group and a saccharide compound comprising a protecting group of General Formula I or General Formula II



I



II


in which

R^1 and R^2 may be the same or different, and is each hydrogen or C_{1-4} alkyl,


- 25 R' is an amino sugar, a glycosylamine, or an oligosaccharide comprising at least one aminosugar or one glycosylamine unit, in which the sugar is coupled via an amino group,

and R'' is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl or substituted cycloalkyl.

7. A resin-linker-saccharide support for solid phase oligosaccharide synthesis, comprising a linker group, a resin, and a saccharide compound comprising a protecting group of General Formula I or General Formula II



I



II

10

in which

R¹ and R² may be the same or different, and is each hydrogen or C₁₋₄ alkyl,

- R' is an amino sugar, a glycosylamine, or an oligosaccharide comprising at least one aminosugar or one glycosylamine unit, in which the sugar is coupled via an amino group,

and R'' is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl or substituted cycloalkyl.

8. A method of solution phase synthesis of oligosaccharides, comprising the step of sequentially linking mono- or oligosaccharide groups to a linker-saccharide complex as defined in Claim 6.

9. A method according to Claim 8 for synthesis of aminoglycoside compounds.

10. A method of solid-phase synthesis of oligosaccharides, comprising the step of sequentially linking mono- or oligosaccharide groups to a resin-linker-sugar support as defined in Claim 7.

11. A method according to any one of Claims 8 to 10 for combinatorial synthesis.

12. A kit for solid-phase synthesis or combinatorial synthesis of oligosaccharides, comprising a linker-saccharide complex according to Claim 6 or a resin-linker-saccharide support according to Claim 7, and optionally
- 5 also comprising one or more further reagents such as partially or differentially activated, fully protected saccharides, protecting agents, deprotecting agents, resins and/or solvents suitable for solid phase or combinatorial synthesis.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 98/00131

A. CLASSIFICATION OF SUBJECT MATTER																						
Int Cl ⁶ : C07H 1/00, 5/06, 15/18 CO8B 37/00																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols)																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CHEMICAL ABSTRACTS, Substructure Search																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
E	AU, A 38422/97 (ALCHEMIA PTY LTD) 19 March 1998 See whole document	1-12																				
A	I.A.Nash et al., Tetrahedron Letters, 1996, 37(15), 2625-2628, "Dde - A Selective Primary Amine Protecting Group: A facile Solid Phase Synthetic Approach to Polyamine Conjugates."	1-12																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input type="checkbox"/> See patent family annex																						
<p>* Special categories of cited documents:</p> <table border="0"><tr><td>"A"</td><td>document defining the general state of the art which is not considered to be of particular relevance</td><td>"T"</td><td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>"E"</td><td>earlier document but published on or after the international filing date</td><td>"X"</td><td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>"L"</td><td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>"Y"</td><td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>"O"</td><td>document referring to an oral disclosure, use, exhibition or other means</td><td>"&"</td><td>document member of the same patent family</td></tr><tr><td>"P"</td><td>document published prior to the international filing date but later than the priority date claimed</td><td></td><td></td></tr></table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 28 April 1998		Date of mailing of the international search report - 7 MAY 1998																				
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer MATTHEW FRANCIS Telephone No.: (02) 6283 2424																				

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 98/00131

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J.Chem.soc., Chem.commun., 1993, (9), 778-9 "A Novel Lysine - protecting Procedure for continuous Flow Solid Phase Synthesis of Branched Peptides." Cited in the application	1-12
A	Pept. 1994, Proc.Eur.Pept. Symp., 23rd (1995), Meeting Date 1994, 153-154. "Novel Protecting Group for Fmoc/tBu Solid-phase synthesis of Side-chain Carboxy-modified Peptides (W.C Chan et al)	1-12

98/08799

(12) **PATENT**
(19) **AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 199738422 B2**
(10) Patent No. **728149**

(54) Title
Oligosaccharide synthesis

(51)⁷ International Patent Classification(s)
C07C 059/353 C07C 257/06
C07C 059/90 C07H 005/06
C07C 069/716 C08J 007/14
C07C 069/738 C08J 007/16
C07C 229/32

(21) Application No: **199738422**

(22) Application Date: **1997.08.26**

(87) WIPO No: **WO98/08799**

(30) Priority Data

(31) Number	(32) Date	(33) Country
PO 1905	1996.08.26	AU

(43) Publication Date : **1998.03.19**

(43) Publication Journal Date : **1998.05.14**

(44) Accepted Journal Date : **2001.01.04**

(71) Applicant(s)
Alchemia Pty. Ltd.

(72) Inventor(s)
Istvan Toth; Gyula Dekany; Barry Kellam

(74) Agent/Attorney
GRIFFITH HACK,GPO Box 1285K,MELBOURNE VIC 3001